INT247970

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2008
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 5.37
Pain Relevance 1.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CLTC) mitosis (CLTC) mitochondrion (CLTC)
vesicle-mediated transport (CLTC) structural molecule activity (CLTC) plasma membrane (CLTC)
Anatomy Link Frequency
hepatocyte 1
CLTC (Homo sapiens)
Pain Link Frequency Relevance Heat
Neuropathic pain 52 100.00 Very High Very High Very High
fifth nerve 13 92.28 High High
Pain 89 91.80 High High
primary somatosensory cortex 29 82.60 Quite High
Inflammation 4 82.20 Quite High
imagery 16 74.24 Quite High
agonist 2 73.52 Quite High
allodynia 11 63.84 Quite High
Somatosensory cortex 18 60.84 Quite High
depression 8 7.92 Low Low
Disease Link Frequency Relevance Heat
Infection 416 100.00 Very High Very High Very High
Neuropathic Pain 70 100.00 Very High Very High Very High
Apoptosis 5 99.96 Very High Very High Very High
Rupture 17 99.40 Very High Very High Very High
Recurrence 21 97.20 Very High Very High Very High
Cirrhosis 8 97.08 Very High Very High Very High
Targeted Disruption 17 96.96 Very High Very High Very High
Disease 141 96.76 Very High Very High Very High
Hepatitis C Virus Infection 115 95.92 Very High Very High Very High
Pain 110 91.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Based on the prior in vitro determination of 300 U being a safe and effective CHC dose for cord rupture, the first patient was given an injection of 300 U – this failed to achieve cord rupture.
Regulation (effective) of CHC associated with rupture
1) Confidence 0.28 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2988615 Disease Relevance 1.41 Pain Relevance 0
The knock-down of ATP6V0A1 and CLTC (at concentration of 50 nM) produced the strongest inhibition of DENV infection. siRNA smart pool-based deconvolution assays targeting CLTC, AP2B1, DNM2, ARRB1, ATP6V0A1 and ARPC1B were also performed to ensure that inhibitory effects on DENV infection observed in the primary screen was specific and not due to off-target gene effects of the siRNA primary screen. 30 nM of each specific individual siRNA of the smart pool (4 specific siRNAs) directed against each of the respective genes were reverse transfected into RD cells and subsequently subjected to DENV infection.
Regulation (targeting) of CLTC associated with targeted disruption and infection
2) Confidence 0.22 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.72 Pain Relevance 0
To determine whether the different serotypes of DENV (DENV 1 to 4) utilized clathrin-mediated endocytosis to gain entry into Huh7 cells, cells were reverse-transfected with different concentration of siRNAs that target clathrin heavy chain (CLTC) and subjected to DENV 1 to 4 infection (MOI of 1).
Regulation (target) of clathrin heavy chain associated with infection
3) Confidence 0.22 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.43 Pain Relevance 0.04
Reverse-transfection of Huh 7 cells with siRNAs targeting CLTC, AP2B1, DNM2, ARRB1, ATP6V0A1 and ARPC1B showed dosage dependent reductions in the levels of the respective proteins when compared to the levels in the mock-transfected cells (Figure 3).
Regulation (targeting) of CLTC
4) Confidence 0.22 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.50 Pain Relevance 0
To determine whether the different serotypes of DENV (DENV 1 to 4) utilized clathrin-mediated endocytosis to gain entry into Huh7 cells, cells were reverse-transfected with different concentration of siRNAs that target clathrin heavy chain (CLTC) and subjected to DENV 1 to 4 infection (MOI of 1).
Regulation (target) of CLTC associated with infection
5) Confidence 0.19 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.48 Pain Relevance 0.04
Increased rates of hepatocyte apoptosis and activated caspases have been observed in CHC.36 Antifibrotic agents such as angiotensin receptor blockers and drugs regulating apoptosis pathways have been used in patients with CHC with compensated cirrhosis.37 Inhibiting caspases with a specific pancaspase inhibitor may play an important role in HCV treatment and cirrhosis in the future.
Regulation (regulating) of CHC in hepatocyte associated with cirrhosis, hepatitis c virus infection, apoptosis and infection
6) Confidence 0.11 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731021 Disease Relevance 1.23 Pain Relevance 0.08
Although no thickness changes between TNP and HC were noticed in the craniofacial sections (1 and 2) of the precentral gyrus, we observed significant thinning in sections (3 and 4) that may represent the hand [16] of MI in the contralateral side to the pain (p<0.0007).
Neg (no) Regulation (changes) of HC associated with pain and neuropathic pain
7) Confidence 0.10 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2561059 Disease Relevance 0.60 Pain Relevance 0.91
However, in animals that had undergone monocular enucleation, column-like patches of c-Fos and MHCI-HC immunoreactivity were visible throughout layer IV of V1 (Figure 9C and 9D and Additional file 6).
Regulation (immunoreactivity) of MHCI-HC
8) Confidence 0.02 Published 2011 Journal Behav Brain Funct Section Body Doc Link PMC3023691 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox